Christina Rossi

Christina Rossi's Title

Christina Rossi currently holds the position of Chief Operating Officer (COO), a role that underscores her extensive experience and leadership in the pharmaceutical and biotechnology sectors. As COO, she is responsible for overseeing the day-to-day administrative and operational functions of the company, ensuring that the business runs efficiently and effectively while aligning with strategic goals. Her role is pivotal in driving organizational success and operational excellence.

Christina Rossi's Experience

With over 20 years of global pharmaceutical and biotechnology experience, Christina Rossi has built a distinguished career marked by significant contributions to the industry. She has previously served as Chief Commercial Officer from October 2018 to April 2022, where she played a critical role in overseeing the commercial launches of AYVAKIT (avapritinib) and GAVRETO (pralsetinib) across multiple indications and geographies. Her tenure at Sanofi Genzyme as the Multiple Sclerosis (MS) Business Unit Head for North America saw her managing the financial performance of the MS franchise, increasing market share, and launching new therapies. Rossi has also held various strategic roles at Biogen Inc., including Head of Commercial Strategy for Eidetica Biopharma GmbH and U.S. Brand Leader for TYSABRI (natalizumab).

Christina Rossi's Education and Expertise

Christina Rossi is highly educated, holding a Bachelor of Science (B.S.) in biology, cum laude, from Duke University and an MBA from Harvard Business School. Her educational background provides a strong foundation in both the scientific and business aspects of the pharmaceutical and biotechnology industries. This unique blend of expertise has enabled her to navigate complex commercial landscapes, optimize operations, and lead successful market access efforts in the U.S. and Europe.

Christina Rossi's Achievements

Throughout her career, Christina Rossi has achieved numerous milestones that highlight her leadership and strategic acumen. Notably, she oversaw the commercial infrastructure creation and led successful market access efforts for AYVAKIT (avapritinib) and GAVRETO (pralsetinib), ensuring their availability across multiple geographies. At Sanofi Genzyme, she increased market share for existing products and spearheaded the launch of new therapies, significantly impacting the treatment landscape for multiple sclerosis. Additionally, her roles at Biogen Inc. and consulting experience at the Boston Consulting Group have further solidified her reputation as a key player in the pharmaceutical industry.

Christina Rossi's Board Membership

Christina Rossi also contributes her expertise as an independent director on the board of Xilio Therapeutics, where she is a member of the compensation committee. Her role on the board allows her to leverage her extensive industry knowledge to guide strategic decisions, enhance corporate governance, and contribute to the overall success of the organization. Her involvement underscores her commitment to advancing the biotechnology and pharmaceutical sectors through leadership and innovation.